METTL13 was downregulated during the late stages of the disease and maintained at low levels throughout tumor progression based on TNM staging, which suggested that METTL13 may be important during bladder cancer development and progression and low expression level of METTL13 may reflect poor prognosis of bladder cancer patients. Here, METTL13 is linked to urinary bladder carcinoma.